Entrada Therapeutics Inc (TRDA)
NASDAQ:TRDA
Want to see TRDA full AI Analyst Report?
Total Valuation
Entrada Therapeutics Inc has a market cap or net worth of $228.65M. The enterprise value is $207.78M.
Market Cap$228.65M
Enterprise Value$207.78M
Share Statistics
Entrada Therapeutics Inc has 38,820,618 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding38,820,618
Owned by Insiders35.98%
Owned by Institutions36.84%
Financial Efficiency
Entrada Therapeutics Inc’s return on equity (ROE) is -0.47 and return on invested capital (ROIC) is -43.69%.
Return on Equity (ROE)-0.47
Return on Assets (ROA)-0.38
Return on Invested Capital (ROIC)-43.69%
Return on Capital Employed (ROCE)-0.44
Revenue Per Employee138.91K
Profits Per Employee-785.52K
Employee Count183
Asset Turnover0.07
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Entrada Therapeutics Inc is ―. Entrada Therapeutics Inc’s PEG ratio is 0.00996.
PE Ratio―
PS Ratio16.73
PB Ratio1.39
Price to Fair Value1.39
Price to FCF-3.28
Price to Operating Cash Flow-1.92
PEG Ratio0.00996
Income Statement
In the last 12 months, Entrada Therapeutics Inc had revenue of 25.42M and earned -143.75M in profits. Earnings per share was -3.47.
Revenue25.42M
Gross Profit21.32M
Operating Income-156.00M
Pretax Income-142.83M
Net Income-143.75M
EBITDA-142.40M
Earnings Per Share (EPS)-3.47
Cash Flow
In the last 12 months, operating cash flow was -131.70M and capital expenditures 59.00K, giving a free cash flow of -131.64M billion.
Operating Cash Flow-131.70M
Free Cash Flow-131.64M
Free Cash Flow per Share-3.39
Dividends & Yields
Entrada Therapeutics Inc pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.17
52-Week Price Change-26.53%
50-Day Moving Average12.03
200-Day Moving Average9.33
Relative Strength Index (RSI)25.01
Average Volume (3m)466.00K
Important Dates
Entrada Therapeutics Inc upcoming earnings date is Aug 12, 2026, Before Open (Confirmed).
Last Earnings DateMay 7, 2026
Next Earnings DateAug 12, 2026
Ex-Dividend Date―
Financial Position
Entrada Therapeutics Inc as a current ratio of 12.53, with Debt / Equity ratio of 18.37%
Current Ratio12.53
Quick Ratio12.53
Debt to Market Cap0.12
Net Debt to EBITDA0.28
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Entrada Therapeutics Inc has paid 924.00K in taxes.
Income Tax924.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Entrada Therapeutics Inc EV to EBITDA ratio is -2.71, with an EV/FCF ratio of -2.98.
EV to Sales15.18
EV to EBITDA-2.71
EV to Free Cash Flow-2.98
EV to Operating Cash Flow-3.00
Balance Sheet
Entrada Therapeutics Inc has $254.86M in cash and marketable securities with $49.75M in debt, giving a net cash position of $205.11M billion.
Cash & Marketable Securities$254.86M
Total Debt$49.75M
Net Cash$205.11M
Net Cash Per Share$5.28
Tangible Book Value Per Share$7.40
Margins
Gross margin is -598.01%, with operating margin of -613.66%, and net profit margin of -565.48%.
Gross Margin-598.01%
Operating Margin-613.66%
Pretax Margin-561.84%
Net Profit Margin-565.48%
EBITDA Margin-560.17%
EBIT Margin-561.84%
Analyst Forecast
The average price target for Entrada Therapeutics Inc is $19.50, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$19.50
Price Target Upside39.39% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast-96.67%
EPS Growth Forecast-559.52%